Targeted Medical Pharma (TRGM) Stock Price
Targeted Medical Pharma Price
Revenue at Targeted Medical Pharma has contracted by 11.3% per year over the past 7 years to 5.26 M USD. Earnings per share have declined at 2.1% per year over the last 2 years. For Targeted Medical Pharma, the net margin of -57.9% is down versus -47.4% a few years ago.
Targeted Medical Pharma stock price
Targeted Medical Pharma business model & stock analysis
Frequently asked questions about Targeted Medical Pharma
Targeted Medical Pharma Inc (TMP) operates under a unique business model in the pharmaceutical industry. The company specializes in developing and commercializing innovative prescription medical food products, primarily for the management of chronic diseases. TMP aims to bridge the gap between traditional pharmaceutical drugs and nutritional therapies through targeted medical foods. These products are formulated with specific ratios of pharmaceutical-grade nutrients to address the distinctive nutritional needs of patients with various conditions. By focusing on developing effective and scientifically validated solutions, TMP strives to improve patient outcomes and offer alternative treatment options for chronic diseases.
Targeted Medical Pharma Inc is primarily active in the healthcare and pharmaceutical industries.
Targeted Medical Pharma Inc faces competition from several companies in the market. Some of its main competitors include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc., and GlaxoSmithKline. These companies also operate in the pharmaceutical industry, offering a range of medical products and therapeutics. Targeted Medical Pharma Inc strives to differentiate itself through its unique offerings, innovative solutions, and focus on specific medical conditions. By continually evolving and delivering effective treatments, Targeted Medical Pharma Inc aims to stay competitive and fulfill the needs of patients and healthcare providers in the market.
Targeted Medical Pharma Inc is a renowned pharmaceutical company with a rich history and background. Founded in 1999, Targeted Medical Pharma has been dedicated to developing innovative medical solutions. The company specializes in creating and commercializing prescription medical foods for the management of chronic diseases. With a strong focus on evidence-based medicine, Targeted Medical Pharma strives to improve patient outcomes and enhance overall quality of life. Their commitment to research, development, and partnerships has earned them a prominent position in the industry. Targeted Medical Pharma Inc continues to drive advancements in the medical field by delivering effective and safe treatments for patients worldwide.
Targeted Medical Pharma Inc has achieved several significant milestones. The company successfully developed and launched innovative pharmaceutical products in the field of chronic disease management. It received FDA clearance for its medical food products, including Theramine® and Sentra AM®. Targeted Medical Pharma Inc also secured strategic partnerships and collaborations, enabling them to expand their market reach and enhance their research capabilities. The company has consistently demonstrated its commitment to delivering high-quality therapeutic solutions to patients and healthcare professionals. With its focus on innovation and dedication to improving patient outcomes, Targeted Medical Pharma Inc continues to drive advancements in the pharmaceutical industry.
Targeted Medical Pharma Inc primarily operates in the United States and focuses on the domestic market.
Targeted Medical Pharma Inc is committed to delivering innovative medical solutions that improve patient outcomes. Their corporate philosophy revolves around the core values of integrity, excellence, and patient-focused care. With a strong emphasis on research and development, Targeted Medical Pharma Inc aims to develop and commercialize pharmaceutical products that address unmet medical needs. By prioritizing patient well-being, the company strives to provide effective and safe treatments. Through their dedication to scientific advancements and ethical practices, Targeted Medical Pharma Inc sets a high standard in the medical industry.
Converted at the current exchange rate, the Targeted Medical Pharma share trades at 0.00 EUR (0.00 USD).
The company Targeted Medical Pharma Inc is a biopharmaceutical company that focuses on the development and marketing of innovative therapy products for various diseases. The business model of Targeted Medical Pharma is based on the production of pharmaceutical agents that are specifically tailored to the needs of patients. The company is divided into three business units: TmedPharma, TmedCRO, and TmedRx. TmedPharma specializes in the development of therapeutics for chronic metabolic disorders, as well as neurological and immunological diseases. TmedCRO offers clinical study services to other pharmaceutical companies, while TmedRx distributes dietary supplements and medical devices directly to consumers. Targeted Medical Pharma's products include therapeutics such as Theramine, a patented amino acid agent used to treat pain and inflammation. Avatrol is another product developed for the treatment of hemorrhoids. The company also offers NeuroReplete, a preparation for the treatment of metabolic disorders and neurological diseases. Another important aspect of Targeted Medical Pharma's business model is its partnership with leading medical institutions and organizations. The company collaborates with renowned universities and research institutions to test the effectiveness and safety of its products through clinical studies and research. These partnerships also serve as important marketing tools to increase awareness of the Targeted Medical Pharma brand among physicians and other healthcare professionals. Targeted Medical Pharma sells its products through a network of pharmacies, clinics, physicians, and online retailers. The company also holds several patents on its products and technologies, giving it a competitive advantage in the industry. In summary, Targeted Medical Pharma's business model is focused on developing and marketing innovative therapeutics for chronic metabolic disorders and neurological diseases. The company has three business units specializing in therapeutics development, clinical study services, and direct sales of dietary supplements and medical devices. Targeted Medical Pharma collaborates with leading institutions to test the effectiveness and safety of its products, and holds patents on its products and technologies, providing it with a competitive advantage in the industry.
The revenue cannot currently be calculated for Targeted Medical Pharma.
The profit cannot currently be calculated for Targeted Medical Pharma.
The P/E ratio cannot be calculated for Targeted Medical Pharma at the moment.
The P/S cannot be calculated for Targeted Medical Pharma currently.
The Eulerpool Quality Score for Targeted Medical Pharma is 1/10.
The ISIN of Targeted Medical Pharma is US8761401046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Targeted Medical Pharma is A1JFCJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Targeted Medical Pharma is TRGM. The ticker symbol is used to trade Targeted Medical Pharma shares on the stock exchange.
Targeted Medical Pharma stock
Targeted Medical Pharma Peer Group
Targeted Medical Pharma Ticker
Targeted Medical Pharma FIGI
All fundamentals and in-depth analysis of Targeted Medical Pharma
Our stock analysis for Targeted Medical Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Targeted Medical Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.